EFPIA - NEWSLETTER

EFPIA Newsletter 09 June 2022

Research-based biopharmaceutical industry on the TRIPS waiver discussions at WTO Ministerial Conference (MC12)

The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework as proposed in the “Quad compromise” is unnecessary and harmful to innovation. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk. It will undermine innovation and industry’s ability to partner, invest at risk, and respond quickly to future pandemics.

News

03 June 2022 EFPIA statement on the concerning impact of the In Vitro Diagnostic Regulation

Clinical trials in Europe might be reduced and access to novel therapies for patients delayed

Blogs

07 June 2022 Europe’s Beating Cancer Plan is an investment, not a cost

With prevention and early diagnosis at the core, we call on the European Commission to continue to ensure that supporting...

08 June 2022 Be ambitious! Setting policy objectives for blood cancer

It’s a great moment for the hematology community to stand up and advocate for explicit policy action on blood cancers...

Back innovation, boost access

Innovation is only meaningful if patients get access to it. That’s why we are stepping up measures to help deliver faster, more equitable access to medicines for millions of patients across the EU.
Read more

Let's get medicines to patients faster

Patients in one part of Europe should not have to wait 7 times longer for a new medicine than those in another country.

Let's make access to medicines fairer

All European countries don’t have the same capacity to pay for healthcare. If we want to create a more equitable system, we need to discuss a new model for equity-based tiered pricing in Europe. Read more: https://bit.ly/3JeJNka

Join us on 29 June

Job offer at IML

European Project Manager Country Engagement 08 June 2022 (IML)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶